TheBodyPro: Expert analysis from Benjamin Young, M.D., Ph.D.
Are we ever going to see broadly neutralizing antibodies (bNAbs) emerge as a widely utilized HIV treatment method? It still feels too early to place any bets, but newly published results from the much-heralded RIO study are certainly cause for optimism. They allow us to envision a future in which a combination of approaches helps our patients live untethered from the need to take HIV medications daily (or weekly, or monthly, or quarterly).
This analysis reports the 20-week results of RIO, a double-blind, randomized, placebo-controlled study evaluating whether two long-acting bNAbs could delay HIV rebound after participants stopped antiretroviral therapy. The two bNAbs, called 3BNC117-LS and 10-1074-LS, target conserved regions on the HIV envelope glycoprotein and can neutralize a broad range of HIV strains.
Read the full analysis here.
Source : TheBodyPro
Related HIV and Co-Infections News
-
[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment
-
aidsmap: Switching to an integrase inhibitor can raise diabetes risk in people with HIV
-
TheBodyPro: Can long-acting regimens solve virologic failure in heavily treatment-experienced people with HIV?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.